---
title: "Fulcrum Therapeutics Announces $175 Million Public Offering"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/269372807.md"
description: "Fulcrum Therapeutics announced a $175 million public offering, pricing 11,851,853 shares of common stock and pre-funded warrants for 1,111,193 shares. The offering closes on December 11, 2025, with proceeds for corporate purposes like R&D and acquisitions. Analysts rate FULC stock as Hold with a $16 target. Fulcrum, a biopharmaceutical firm, focuses on rare genetic diseases, with its lead program targeting sickle cell disease."
datetime: "2025-12-11T11:30:49.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/269372807.md)
  - [en](https://longbridge.com/en/news/269372807.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/269372807.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/269372807.md) | [繁體中文](https://longbridge.com/zh-HK/news/269372807.md)


# Fulcrum Therapeutics Announces $175 Million Public Offering

### Claim 50% Off TipRanks Premium and Invest with Confidence

-   Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential

Fulcrum Therapeutics ( (FULC) ) has shared an announcement.

On December 10, 2025, Fulcrum Therapeutics announced the pricing of its underwritten public offering, which includes 11,851,853 shares of common stock and pre-funded warrants to purchase up to 1,111,193 shares, raising gross proceeds of $175 million. The offering is expected to close on December 11, 2025, and the net proceeds will be used for general corporate purposes, including working capital, research and development, and potential acquisitions, positioning Fulcrum to enhance its operations and market presence.

The most recent analyst rating on (FULC) stock is a Hold with a $16.00 price target. To see the full list of analyst forecasts on Fulcrum Therapeutics stock, see the FULC Stock Forecast page.

**Spark’s Take on FULC Stock**

According to Spark, TipRanks’ AI Analyst, FULC is a Neutral.

Fulcrum Therapeutics’ overall stock score is driven by strong technical momentum and promising clinical trial results, despite challenges in profitability and valuation concerns. The company’s robust financial position and strategic growth plans provide a solid foundation for future advancements.

To see Spark’s full report on FULC stock, click here.

**More about Fulcrum Therapeutics**

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease. Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression.

**Average Trading Volume:** 1,173,075

**Technical Sentiment Signal:** Buy

**Current Market Cap:** $790.1M

### 相关股票

- [Fulcrum Therapeutics (FULC.US)](https://longbridge.com/zh-CN/quote/FULC.US.md)

## 相关资讯与研究

- [Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | FULC Stock News](https://longbridge.com/zh-CN/news/278172807.md)
- [Should You Buy PAYP Stock After the PayPay IPO?](https://longbridge.com/zh-CN/news/278572462.md)
- [SUMA Acquisition Corporation Announces Pricing of $150,000,000 Initial Public Offering | SUMA Stock News](https://longbridge.com/zh-CN/news/278623081.md)
- [Suma Acquisition Prices $150 Million Initial Public Offering](https://longbridge.com/zh-CN/news/278697542.md)
- [Pono Capital Four, Inc. Announces Pricing of $120,000,000 Initial Public Offering | PONO Stock News](https://longbridge.com/zh-CN/news/278956585.md)